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OBJECTIVES The goal of this research was to study coronary atherosclerosis in patients with type 2 diabetes
compared with patients without diabetes according to the new definition of diabetes
advocated by the American Diabetes Association in 1997.
BACKGROUND Patients with diabetes (fasting plasma glucose above 7.0 mM/L) have a higher risk of
cardiovascular death. The correlation with the pattern and severity of their coronary
atherosclerosis, especially in the new patients with “mild” diabetes (7.0 mM/L # fasting
plasma glucose , 7.8 mM/L), remains unclear.
METHODS A cohort of 466 patients undergoing coronary angiography but free of any previous infarction,
coronary intervention and insulin therapy were prospectively recruited. Ninety-three had
diabetes (fasting plasma glucose . 7.0 mM/L or hypoglycemic oral treatment). Five
angiographic indexes were calculated to describe severity and extent of coronary atheroscle-
rosis.
RESULTS Overall, patients with diabetes had more diffuse coronary atherosclerosis, a greater prevalence
of mild, moderate and severe stenoses and a two-fold higher occlusion rate than patients
without diabetes, even after adjustment for age, gender, body mass index, hypertension, lipid
parameters, smoking, family history of cardiovascular events and ischemic symptoms. Patients
with “mild diabetes” had a coronary atherosclerosis pattern more similar to patients with
normal fasting plasma glucose than to patients formerly defined as diabetic according to the
World Health Organization criteria, except that they had a higher prevalence of ,50%
stenoses.
CONCLUSIONS In patients with type 2 diabetes, those with 7.0 mM/L # fasting plasma glucose , 7.7 mM/L
have a slightly greater prevalence of mildly severe lesions that may partly explain their higher
cardiovascular event rate. (J Am Coll Cardiol 2001;37:1543–50) © 2001 by the American
College of Cardiology
Type 2 diabetes mellitus is associated with a two- to
four-fold increased incidence of myocardial infarction and
cardiac death (1,2). This increased risk of major cardiac
events is thought to be mostly related to accelerated devel-
opment of coronary atherosclerosis, although this relation-
ship remains controversial. An association with increased
severity of coronary artery disease (CAD) in patients with
diabetes has been previously shown (3–5) but has been
questioned in more recent angiographic (6) and histologic
(7) studies and might be accounted for by other confound-
ing risk factors that frequently affect patients with diabetes,
such as dyslipidemia, hypertension and obesity. In 1997, the
American Diabetes Association (ADA) Expert Group (8)
lowered the threshold value for fasting plasma glucose
(FPG) to define diabetes, namely $7.0 mM/L (126 mg/dl),
in order to better fit the results of the 2-h oral glucose
tolerance test, reduce the incidence of undetected diabetes
and better predict the risk of microvascular complications.
The ADA fasting definition may have an impact on the
association between type 2 diabetes and coronary athero-
sclerosis.
In 466 patients with a detailed description of the coronary
anatomy, we, therefore, investigated the patterns of CAD in
patients with diabetes according to the ADA definition. We
also analyzed the changes in patterns of coronary athero-
sclerosis of patients categorized across increasing degrees of
hyperglycemia, from normal plasma glucose to diabetes.
METHODS
Patient selection. Five hundred twenty-two patients re-
ferred to our institution for coronary angiography were
consecutively and prospectively screened for recruitment.
The selection criteria were: 1) indication for coronary
angiography (9); 2) no history of coronary intervention
(whether instrumental or surgical), organ transplantation or
renal hemodialysis; 3) no type 1 (insulin-dependent) diabe-
tes mellitus; and 4) no history of myocardial infarction nor
any Q waves on the 12-lead electrocardiogram (ECG).
Four hundred and sixty-six patients (88%) were finally
considered for analysis; 32 were excluded for incomplete
clinical or biological data, and 22 were excluded because
angiogram quality was unsuitable for quantification of the
CAD. Clinical presentation was stable angina in 155
patients (33%), unstable angina (10) in 155 patients (33%),
silent ischemia in 12 patients (3%), atypical chest pain in 48
patients (10%) and miscellaneous (preoperative assessment,
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dilated cardiomyopathy, valvular heart disease) in 96 pa-
tients (21%).
Reported clinical data included personal medical history,
risk factors, history of medications, family history of cardio-
vascular events and diabetes, height, weight and blood
pressure recorded twice in the sitting position. The bio-
chemical parameters were obtained after a 12-h fasting
period during an overnight hospital stay and included FPG
(glucose oxidize method), serum total cholesterol and its
high and low density lipoprotein (HDL and LDL) subfrac-
tions and triglyceride levels. Hemoglobin A1c was not
routinely obtained and was not used in this study.
Diabetes was defined as the intake of a diabetic diet
or oral hypoglycemic agents or a FPG above 7 mM/L
(126 mg/dl) according to the new ADA criteria (8). Patients
without diabetes were further subdivided into normal pa-
tients (FPG , 6.1 mM/L) and patients with impaired
fasting glucose (6.1 mM/L # FPG , 7.0 mM/L). Patients
with diabetes were also subdivided into patients with newly
diagnosed “mild” diabetes (7.0 mM/L # FPG , 7.8
mM/L) and patients with diabetes according to the former
World Health Organization (WHO) definition. Since the
75 g oral glucose tolerance test was not routinely performed,
by convention in this study we consider WHO-diabetes as
the intake of any oral hypoglycemic agents or a FPG $ 7.8
mM/L (140 mg/dl) (11). Hypertension was defined as the
intake of antihypertensive drugs or two measurements of the
systolic/diastolic blood pressure above 160/95 mm Hg.
Hypercholesterolemia was defined as the intake of a
cholesterol-lowering agent or the combination of total
cholesterol above 5.2 mM/L and LDL above 3.3 mM/L.
Patients who currently smoked or who had quit smoking for
less than two years were considered smokers. Silent isch-
emia was defined as evidence of ischemia without any
symptom of angina, either at rest using 12-lead ECG or in
daily activities using Holter ST-segment monitoring.
Quantitative coronary study. The coronary angiograms
were independently analyzed by two of the same three
experienced cardiologists throughout the study who were
unaware of the clinical and biological data. Each of the 15
coronary segments (12) was graded according to its most
severe diameter reduction as follows: grade 0, ,25% steno-
sis; grade 1, ,50% stenosis; grade 2, ,75% stenosis; grade
3, $75% stenosis; grade 4, occlusion defined as a .95%
diameter stenosis with a severely reduced or no antegrade
flow (13). Segments downstream of grade 4 stenoses or less
than 1-mm diameter vessels were not analyzed. Discrepan-
cies in quantification between the observers were resolved by
quantitative analysis of the disputed segment using the
ARTREK software (ImageComm Systems, Santa Clara,
California). Ninety-five angiograms had to be reviewed to
reach a consensus (20%).
Four scores were derived to describe coronary atheroscle-
rosis. The “coronary score” was defined by the number of
coronary arteries exhibiting a stenosis greater than 75%
diameter reduction (grade 3 or 4) (14). Stenosis of the left
main coronary artery greater than 50% was considered a
two-vessel CAD. The “extent score” was the number of
segments exhibiting lesions greater than or equal to grade 1,
adjusted to 15 coronary segments. The “severity score” was
calculated as the average grade of the diseased coronary
segments (i.e., graded 1 or more). The “atherosclerotic
score” was calculated as the average severity of all analyzable
segments. Interobserver variability was 2.0%, 6.0%, 10.4%
and 2.4% for the “coronary score,” the “extent score,” the
“severity score” and the “atherosclerotic score,” respectively.
Atherosclerosis involving the left main, the proximal left
anterior descending and circumflex arteries and the first
three segments of the right coronary artery was considered
proximal coronary atherosclerosis, while atherosclerosis in-
volving the other coronary segments was considered distal
coronary atherosclerosis.
Statistical analysis. Data were analyzed using the SAS
package (SAS Institute, Cary, North Carolina). Unless
otherwise stated, values are expressed as the mean 6 1 SD.
Two-group comparisons were performed by the unpaired t
test. Multivariate analyses were performed by linear regres-
sion with a forward stepwise selection of explaining variables
to enter into the regression, with p value #0.05.
RESULTS
Characteristics of patients with and without diabetes.
The clinical and biological data are displayed in Table 1.
Patients with diabetes were statistically older, had greater
overweight, hypertension and familial history of diabetes
than patients without diabetes, but clinical presentation was
not significantly different. Among the 93 patients with
diabetes, 53 (57%) had been taking at least one hypoglyce-
mic agent for a median of six years (range 1 month to
27 years). Among the 40 patients with newly discovered
diabetes, 20 had a FPG between 7 mM/L and 7.7 mM/L,
and 20 had a FPG above 7.8 mM/L. In 66% of both the
patients with and without diabetes, left ventricular ejection
fraction was calculated by ventricular angiography. It was in
the normal range and similar in the two groups.
As expected, patients with diabetes had higher triglycer-
ide levels and lower HDL-cholesterol levels than patients
without diabetes but similar total and LDL-cholesterol
levels. The rate of cholesterol-lowering agents intake was
similar with a median intake duration of three years (range
0 to 34 years) in both groups. Only 54% of the patients
Abbreviations and Acronyms
ADA 5 American Diabetes Association
CAD 5 coronary artery disease
ECG 5 electrocardiogram
FPG 5 fasting plasma glucose
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
WHO 5 World Health Organization
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without diabetes and 65% of the patients with diabetes were
taking a platelet-blocking agent, but this difference was not
significant. However, duration of antiplatelet therapy was
slightly longer (p 5 0.014) in patients with diabetes (me-
dian 5 months [0 to 24 years]) than it was in patients
without diabetes (1 month [0 to 16.5 years]). No significant
clinical and biological differences were observed between
patients with normal fasting glucose and impaired fasting
glucose, as well as between patients with “mild” diabetes and
WHO-defined diabetes (data not shown).
Impact of the new definition of diabetes on the patterns
of coronary atherosclerosis. Coronary atherosclerosis
scores are displayed in Table 2. Patients with diabetes had a
significantly higher prevalence of multivessel disease and
higher “coronary score,” “extent score” and “atherosclerotic
score.” They had a higher number of diseased segments
both in the proximal and the distal locations along the
coronary vasculature than did the patients without diabetes.
There was, however, no interaction between diabetes and
proximal/distal location of diseased segments. Overall, dia-
betic patients had significantly less normal (grade 0) seg-
ments and more mildly (grade 1), moderately (grade 2) and
severely (grade 3) diseased segments. Left main disease was
identified in 5.1% of patients without diabetes and 3.2% of
patients with diabetes (p 5 NS). Occlusion (grade 4) rate
was also higher in patients with diabetes than it was in
patients without diabetes, both in the proximal and distal
locations. However, the difference did not reach significance
for distal occlusions.
After adjustment for other well-known cardiovascular
risk factors, diabetes remained associated with higher “ex-
tent score,” “atherosclerosis score” and occlusion rate (Table
3, A and B). Additional adjustments for symptoms of
angina (combination of chronic and unstable angina)
yielded similar results (data not shown). Forward stepwise
analyses were undertaken to evaluate the best predictors of
the various coronary atherosclerosis scores in the tested
population. The analysis displayed in Table 4 included only
patients not taking any cholesterol-lowering agent. The
Table 1. Population Characteristics
No
Diabetes
(n 5 373)
Type 2
Diabetes
(n 5 93)
p
value*
Age, mean (SD), yr 60.4 (11.3) 62.7 (8.6) 0.03
Men, % 73.2 76.3 0.54
Risk factors
Body mass index (kg/m2),
mean (SD)
25.4 (3.6) 26.9 (3.9) 0.0005
Smoking, % 30.5 23.9 0.22
Hypertension, % 41.0 55.9 0.01
Hypercholesterolemia, % 72.9 71.3 0.76
Family history, %
Diabetes mellitus 13.1 32.0 0.001
Myocardial infarction 30.0 32.9 0.61
Cerebrovascular accident 20.9 25.0 0.44
Cardiovascular death 47.3 55.8 0.16
Any major cardiovascular event 62.0 67.1 0.40
Coronary angiography indication, %
Chronic angina 31.9 38.7
0.24†
Unstable angina 33.2 34.4
Silent ischemia 2.2 4.3
Atypical chest pain 11.3 6.4
Miscellaneous 21.9 16.1
Medical treatment at the time
of study, %
Platelet blocking agent 50.1 60.2 0.08
Cholesterol lowering drug 28.0 35.9 0.14
Beta-blocker 35.5 37.6 0.70
Calcium blocker 41.6 55.9 0.013
Nitrates 47.2 64.5 0.003
ACE inhibitor 22.3 31.2 0.07
Any antihypertensive drug 37.6 52.7 0.008
Biology, mean (SD), mM/L
Total cholesterol 5.78 (1.14) 5.72 (1.15) 0.68
HDL-cholesterol 1.33 (0.42) 1.17 (0.27) 0.0001
LDL-cholesterol 3.71 (0.85) 3.63 (0.82) 0.48
Triglycerides 1.44 (0.84) 1.71 (0.84) 0.0008
Angiographic ejection fraction,
mean (SD), %
67 (10) 66 (13) 0.64
*Two-sided t test, unless otherwise stated; †ANOVA.
Patients were referred for coronary angiography and had no history of myocardial
infarction, coronary revascularization or hemodialysis. Diabetes is defined by a fasting
plasma glucose equal to or greater than 7.0 mM/L or the intake of oral hypoglycemic
agents. Lipid parameters were also obtained in the fasting state.
ACE 5 angiotensin converting enzyme; HDL 5 high density lipoprotein;
LDL 5 low density lipoprotein.
)
Table 2. Coronary Artery Disease Scores in Patients Without
Diabetes and Patients With Type 2 Diabetes
No
Diabetes
(n 5 373)
Type 2
Diabetes
(n 5 93)
p
Value
Coronary score, mean (SD)* 0.50 (0.82) 0.78 (0.91) 0.003
0-vessel, % 68.4 48.4
1-vessel, % 16.9 30.1 0.001
2- or 3-vessels, % 14.8 21.5
Extent score, mean (SD)* 2.45 (2.90) 4.07 (3.71) 0.0002
Severity score, mean (SD)*† 1.68 (0.50) 1.75 (0.47) 0.27
Atherosclerotic score, mean (SD)* 0.29 (0.38) 0.48 (0.48) 0.0004
Occlusion rate, %* 16.9 30.1 0.004
Proximal occlusion rate 8.3 19.4 0.002
Distal occlusion rate 11.8 18.3 0.10
Location of diseased (grade 1 to 4)
segments, mean number of
segments (SD)
Proximal (normalized to
6 segments)*
1.15 (1.45) 1.77 (1.71) 0.002
Distal (normalized to 9 segments)* 1.36 (1.77) 2.40 (2.42) 0.0002
Distribution of segments by severity
grade, mean number of
segments (SD)‡
Normal segments (grade 0) 12.3 (3.0) 10.6 (3.8) 0.0001
Mildly diseased segments
(grade 1)
1.0 (1.3) 1.6 (1.9) 0.03
Moderately diseased segments
(grade 2)
0.6 (1.0) 0.9 (1.4) 0.04
Severely diseased segments
(grade 3)
0.3 (0.7) 0.5 (0.9) 0.05
Occluded segments (grade 4) 0.2 (0.5) 0.4 (0.7) 0.02
*For a definition of these scores, see text; †the severity score is calculated in the 212
patients without diabetes and 68 patients with diabetes with at least one diseased
(equal to or greater than 25% stenosis) coronary segment; ‡the mean number of
segments is normalized to 15 coronary segments.
The number of segments refers to the American Heart Association nomenclature
of 15 coronary segments.
}
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presence of diabetes affected the “extent score,” “atheroscle-
rosis score” and occlusion rate but did not affect the mean
“coronary score,” nor the mean “severity score.” However,
the major predictors were age, gender and hypertension.
Impact of the new categories of hyperglycemia on the
pattern of coronary atherosclerosis. Table 5 shows the
compared angiographic scores between patients with normal
fasting glucose, impaired fasting glucose, “mild” diabetes
and WHO-defined diabetes. The “coronary score,” “athero-
sclerosis score,” “extent score,” occlusion rate, prevalence of
proximal/distal lesions and distribution of severity grade
significantly increased with increasing plasma glucose cate-
gories, as opposed to the “severity score.” There was no
significant difference in these indexes between patients with
normal plasma glucose and patients with impaired fasting
glucose. On the other hand, major and statistically signifi-
cant differences in these angiographic scores were observed
between patients with normal FPG and patients with
WHO-defined diabetes, except for the “severity score.” The
“coronary score,” “extent score,” “atherosclerotic score” and
occlusion rate in patients with “mild” diabetes was interme-
diate between these two patients’ subgroups but overall
more similar to the patients with normal plasma glucose or
impaired fasting glucose than they were to the WHO-
defined patients with diabetes.
Figure 1 depicts the distribution of coronary segments by
severity grade (normalized to 15 segments) and by increas-
ing categories of fasting plasma glucose. It shows that the
patients with “mild” diabetes had a pattern of coronary
lesions very similar to the patients with a FPG below
7 mM/L and significantly fewer segments of a given severity
grade than WHO-defined patients with diabetes. However,
they had a number of mildly diseased coronary segments
significantly greater than patients with normal FPG or
impaired fasting glucose (p 5 0.05) and were similar to the
WHO-defined patients with diabetes.
DISCUSSION
Evidence for a particular pattern of coronary atheroscle-
rosis in patients with diabetes. More than a decade ago,
large cross-sectional studies from Lemp et al. (3) and
Freedman et al. (4) reported a comorbid association be-
tween type 2 diabetes and angiographic severity of CAD.
Changing the definition of diabetes according to the rec-
Table 3. Relationship Between Coronary Artery Disease and
Type 2 Diabetes After Adjustment for Other Cardiovascular
Risk Factors
A: After adjustment on age, gender, body mass index,
hypercholesterolemia, hypertension, family history of major
cardiovascular events and smoking (n 5 375)
No
Diabetes
Type 2
Diabetes
p
Value
Coronary score, mean (SE)* 0.41 (0.06) 0.61 (0.10) 0.08
Atherosclerotic score, mean (SE)* 0.23 (0.03) 0.37 (0.05) 0.004
Extent score, mean (SE)* 1.97 (0.22) 3.14 (0.36) 0.002
Occlusion rate, odds ratio
(95% confidence interval)*
1.00 2.11 (1.14:3.91) 0.02
B: After adjustment on age, gender, body mass index, hypertension,
LDL- and HDL-cholesterol, triglycerides, family history of major
cardiovascular events and smoking (patients taking hypolipemic
drugs excluded) (n 5 256)
No
Diabetes
Type 2
Diabetes
p
Value
Coronary score, mean (SE)* 0.47 (0.07) 0.62 (0.13) 0.30
Atherosclerotic score, mean (SE)* 0.25 (0.03) 0.39 (0.06) 0.04
Extent score, mean (SE)* 2.17 (0.25) 3.31 (0.46) 0.02
Occlusion rate, odds ratio
(95% confidence interval)*
1.00 2.17 (0.98:4.77) 0.06
*For a definition of these scores, see text.
Adjustments were made upon known cardiovascular risk factors. Major cardiovas-
cular events were defined as myocardial infarction, cerebrovascular accident or
cardiovascular death; hypercholesterolemia, hypertension and smoking are defined in
the Methods section.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
Table 4. Forward Stepwise Analysis of the Best Predictors of
the Various Patterns of Coronary Artery Disease in Patients not
Taking Lipid-Lowering Agents
b SE p Value R2
Coronary score*
Age 0.027 0.005 0.0001 0.09
Gender 20.493 0.119 0.0001 0.06
Total R2 0.15
Extent score*
Age 0.102 0.017 0.0001 0.14
Gender 21.713 0.411 0.0001 0.05
Hypertension 0.966 0.373 0.01 0.03
Family history of major
cardiovascular events
0.766 0.374 0.04 0.01
Type 2 diabetes 1.149 0.475 0.02 0.01
LDL-cholesterol 0.469 0.223 0.04 0.01
Total R2 0.25
Severity score*
Age 0.028 0.005 0.0001 0.10
Gender 20.561 0.116 0.0001 0.09
HDL-cholesterol 20.003 0.001 0.06 0.02
LDL-cholesterol 0.171 0.061 0.005 0.01
Total R2 0.22
Atherosclerosis score*
Age 0.012 0.002 0.0001 0.12
Gender 20.228 0.054 0.0001 0.06
Hypertension 0.122 0.049 0.01 0.03
LDL-cholesterol 0.059 0.029 0.04 0.01
Type 2 diabetes 0.137 0.062 0.03 0.01
Family history of major
cardiovascular events
0.086 0.049 0.08 0.01
Total R2 0.25
Occlusion Rate* Odds Ratio [95% CI] p Value
Gender 0.20 [0.07–0.56] 0.002
Age 1.05 [1.01–1.08] 0.01
Hypertension 2.11 [1.08–4.12] 0.03
Type 2 diabetes 2.18 [1.03–4.63] 0.04
*For a definition of these scores, see text.
Family history of major cardiovascular events indicates myocardial infarction,
cerebrovascular accident or sudden death. Gender was coded 0 for women and 1 for
men. All explaining variables are 0 or 1 except age (years) and LDL/HDL cholesterol
levels (mM/L).
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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ommendations of the ADA Expert committee published in
1997 (8) does not change the strength of this association.
However, the angiographic scores that were used to defined
CAD in these pioneering studies only considered severe
lesions: presence of at least one .70% stenosis (3), number
of diseased vessels ($75% stenoses) and summed obstruc-
tion score (4), presence of at least one .50% stenosis (5).
This could have biased the true evaluation of coronary
atherosclerosis and minimized the prognostic importance of
“nonhemodynamically significant” obstructive lesions al-
though these nonsevere lesions could become unstable and
affect outcome by leading to myocardial infarction and
death (15–17). More thorough analysis of the compared
coronary anatomy in this study, including nonstenotic
atheromatous plaques, shows that ADA-defined patients
with diabetes have not only a greater number of diseased
coronary segments (on average 11.6 out of 15 segments)
but also a proportional increased prevalence of mild
(.25%), moderate (.50%) and severe (.75%) stenoses and
a higher prevalence of total or subtotal vessel occlusion
(odds ratio: 1.8 overall, 2.3 for proximal and 1.5 for distal
occlusions), although none of these patients had any history
of infarction or Q waves on the ECG. Besides, presence of
diabetes affects the extent of mild to severe coronary
atherosclerosis, both in the proximal and distal epicardial
arteries. Using quantitative coronary angiography, Pajunen
et al. (6) also found similar average percent diameter
stenosis and atheroma burden (ratio of the plaque area to
the segment length) between 55 type 2 patients with
diabetes and 55 patients without diabetes who were
matched for age, gender and body mass index. As opposed
to our findings, however, the “extent score,” that was
defined by the ratio of the stenosis length to the segment
length, was not significantly different between patients with
and without diabetes. This discrepancy might be due to
differences in population sample and selection and in
quantification methodologies. In few studies, intravascular
ultrasound has been used to provide insights into the
respective role of vascular remodeling and plaque accumu-
lation on lumen compromise in nonstenotic coronary vessels
(18) and stenotic lesions before angioplasty (19). Limited
vessel wall remodeling was observed in both studies but
seemed to be confined to patients with type 1 diabetes,
whereas patients with type 2 diabetes had very similar
plaque burden and vascular remodeling to subjects without
diabetes, at least in obstructive (.50% stenotic) lesions (19).
Further studies of the vessel wall will help us better
understand the underlying mechanisms of this diffuse com-
promise of the coronary arteries in patients with type 2
diabetes.
Interestingly, however, the presence of diabetes did not
seem to affect the average degree of stenosis and plaque
growth since the “severity score” that computes the average
grade of the diseased segments was similar in patients with
and without diabetes. The increased prevalence of total or
subtotal vessel occlusion in patients with diabetes might,
thus, be explained by an intrinsic susceptibility to subacute
arterial thrombosis of moderate stenoses that combines
endothelium dysfunction (20), platelet hyperaggregability
and impaired fibrinolytic activity (21,22).
This association between type 2 diabetes and coronary
atherosclerosis persists after adjustment for other well-
known cardiovascular risk factors, as well as for the presence
of ischemic symptoms, confirming previous findings (3) but
in contradiction with other data based on a different
methodology (histologic analysis of coronary specimens)
and a smaller nondiabetic population (7). Altogether, our
angiographic data further document the independent con-
Table 5. Impact of the New ADA Definition of Impaired Fasting Glucose and Diabetes on
Coronary Artery Disease Scores
No Diabetes
n 5 291
Impaired
Fasting Glucose
n 5 82
Mild
Diabetes
n 5 20
(WHO 1980)
Diabetes
n 5 73
Linear
Trend
p Value
Coronary score, mean (SD)* 0.50 (0.82) 0.45 (0.83) 0.50 (0.61) 0.86 (0.96)§ 0.005
0-vessel, % 67.0 73.2 55.0† 46.6‡§
0.0021-vessel, % 18.2 12.2 40.0† 27.4‡§
2- or 3-vessels, % 14.8 14.6 5.0† 26.0‡§
Extent score, mean (SD)* 2.48 (2.93) 2.35 (2.83) 3.00 (3.12) 4.36 (3.82)§ 0.0001
Severity score, mean (SD)* 1.70 (0.51) 1.59 (0.48) 1.66 (0.49) 1.78 (0.47) 0.43
Atherosclerotic score, mean (SD)* 0.29 (0.38) 0.27 (0.37) 0.31 (0.31) 0.53 (0.51)‡§ 0.0001
Occlusion rate, %* 17.9 13.4 20.0 32.9§ 0.01
Location of diseased segments,
mean number of segments (SD)*
Proximal (max 6 segments)* 1.15 (1.43) 1.14 (1.53) 1.57 (1.58) 1.82 (1.75)§ 0.0009
Distal (max 9 segments)* 1.38 (1.80) 1.28 (1.65) 1.46 (2.10) 2.66 (2.46)§ 0.0001
*For a discussion of these scores, see text; †comparison “no diabetes” versus “mild diabetes” groups with p value # 0.05;
‡comparison “mild diabetes” versus “WHO 1980 diabetes” groups with a p value # 0.05; §comparison “no diabetes” versus
“WHO 1980 diabetes” groups (p values # 0.005).
Patients are categorized according to the new criteria recommended by the ADA (1997 [8]): normal patients (FPG ,6.1
mM/L), patients with impaired fasting glucose (6.1 # FPG , 7.0 mM/L) and patients with diabetes (FPG $ 7.0 mM/L). The
latter patients are subdivided into “mild” diabetes (no antidiabetic treatment and 7.0 # FPG , 7.8 mM/L) and WHO 1980
diabetes (already treated for diabetes or FPG $ 7.8 mM/L).
ADA 5 American Diabetes Association; FPG 5 fasting plasma glucose; WHO 5 World Health Organization.
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Figure 1. Distribution of coronary segments by severity grade and by categories of hyperglycemia. Patients are categorized according to the new criteria of
the American Diabetes Association (1997): normal patients (fasting plasma glucose , 6.1 mM/L; n 5 291); impaired fasting glucose (6.1 mM/L # fasting
plasma glucose , 7.0 mM/L; n 5 82). Diabetic patients are subdivided into “mild” diabetes (no antidiabetic treatment and 7.0 mM/L # fasting plasma
glucose , 7.8 mM/L; n 5 20) and WHO diabetes (already treated for diabetes or fasting plasma glucose $ 7.8 mM/L; n 5 73). Severity grades are defined
in the Methods section. NS for p . 0.05. WHO 5 World Health Organization.
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tribution of hyperglycemia to the initiation or development
of coronary atherosclerosis. However, stepwise analyses
showed that type 2 diabetes was less determinant in coro-
nary atherosclerosis development than age, gender, LDL-
cholesterol or hypertension (Table 4). These findings may
partly explain why vigorous control of blood pressure and
cholesterol levels have a much more beneficial impact on
cardiovascular prognosis than the strict control of glycemia
in patients with diabetes (23,24).
Impact of the new hyperglycemia categories on pattern of
CAD and prognostic implications. From data collected in
the Paris Prospective Study that recruited 6,557 middle-
aged men free of any clinical cardiovascular disease and
followed them for up to 23 years, Charles et al. (25) recently
showed that the risk of death from coronary heart disease
increased with increasing fasting plasma glucose. The age-
adjusted death rate per 1,000 person-years was 2.1, 2.8, 5.4
and 6.3 for men having a fasting plasma glucose categorized
closely according to the revised criteria advocated by the
ADA, namely below 5.8 mM/L, between 5.8 mM/L and
6.9 mM/L, between 6.9 mM/L and 7.8 mM/L and above
7.8 mM/L, respectively. The risk of coronary death was almost
doubled for a fasting plasma glucose above 6.9 mM/L with
a limited additional risk above 7.8 mM/L, substantiating
the choice of 7.0 mM/L as the new threshold to define
diabetes and provide rigorous care. This increased risk of
major cardiac events is usually thought to be attributable to
accelerated or earlier development of coronary atherosclero-
sis. However, although WHO-defined patients with diabe-
tes clearly have greater atherosclerosis indexes than patients
without diabetes that may explain their increased risk of
coronary death, the 20 patients with “mild” diabetes (7.0 to
7.7 mM/L FPG) have a coronary atherosclerosis pattern
very similar to the patients without diabetes and a less severe
pattern than the WHO-defined patients with diabetes.
Only mildly severe (25% to 49% diameter stenosis) lesions
were significantly more prevalent in patients with “mild”
diabetes than they were in patients with normal plasma
glucose and were as prevalent as in the WHO-defined
patients with diabetes (Fig. 1). Young and soft atheroma-
tous plaques are known to be the most prone to rupture and
thrombosis (26 –28), even before they become flow-
limiting. Indeed, these atheromatous plaques of less than
50%-diameter stenosis have been previously shown to rep-
resent more than 60% of the ruptured and thrombotic
plaques causing acute myocardial infarction and sudden
death (15–17). Taken together, these findings suggest that
part of the increased risk of cardiovascular death in “mild”
diabetes (25) might be accounted for by a greater number of
mildly severe, young and vulnerable coronary stenoses, even
in asymptomatic subjects.
Study limitations. In such a study design, selection of the
population may introduce important biases in the findings.
Two-thirds of our patients had ischemic symptoms (wheth-
er chronic or unstable angina) requiring coronary evaluation
and do not represent a standard diabetic population. By
comparison with the United Kingdom Prospective Diabetes
Study (UKPDS) (29), from which patients with significant
ischemic heart disease were excluded, our patients with
diabetes were, on average, 10 years older and more often
men (76.3% vs. 61%), had higher cholesterol levels (mean
total-cholesterol 5.72 mM/L vs. 5.4 mM/L) and took
platelet-blocking (60.2% vs. 1.6%), antihypertensive (52.7%
vs. 12%) and lipid-lowering (35.9% vs. 0.3%) medications
more frequently. Although adjustment on symptoms of
myocardial ischemia did not change the association between
coronary atherosclerosis indexes and diabetes in our study,
these findings should not be extended to the whole diabetic
population, especially to younger patients.
Coronary angiography has its own limitations in the
study of coronary atherosclerosis. It may underestimate the
early development of atheroma (30) since compensatory
enlargement of the vessel wall may initially accommodate
young atheromatous plaques with limited lumen deformation.
On the other hand, infiltrating and diffuse atheroma may also
be underestimated since there may not be normal coronary
segments to be taken as the reference lumen. Differences in
atherosclerosis indexes between patients without diabetes and
patients with type 2 diabetes who are more prone to diffuse
atheroma might be even greater than found in this study. The
use of intravascular ultrasound might overcome this limitation,
but it allows the study of a limited number of coronary plaques
in a given patient as mentioned above.
Plasma glucose was measured once, after an overnight
fasting period. Categorization of a few patients using the
ADA criteria might have been misleading due to intraindi-
vidual variations of FPG levels.
Conclusions. This angiographic study shows that patients
with type 2 diabetes (FPG $ 7 mM/L) have a more diffuse
coronary atherosclerosis, a greater prevalence of stenoses
of any grade and a two-fold higher occlusion rate than
patients without diabetes, even after adjustment for the
other clinical and biological cardiovascular risk factors.
Patients with 7 mM/L to 7.7 mM/L FPG, who are now
considered to be diabetic, have an atherosclerotic pattern more
similar to patients without diabetes than to the former WHO-
defined patients with diabetes, except for a greater prevalence
of ,50% stenoses. This excess in potentially vulnerable coro-
nary lesions may explain the increased cardiac mortality ob-
served in this subset of patients and substantiate the need for
specific cardiovascular and metabolic care in these patients.
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